Developer docs
API playgroundTry for free, no card

Search company profiles

Vision Sciences

Full company profile

uuid0035u1n

Namestring
Vision Sciences
Company typeenum
Private
Founded yearint
1987
Short descriptiontext

Vision Sciences is a medical device company that develops flexible endoscopes engineered to reduce cross-contamination risk in clinical settings. Founded in 1987 and headquartered in Orangeburg, it historically served healthcare providers before its NASDAQ delisting.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOrangeburg, United States
HQ citystring
Orangeburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
flexible endoscopes, medical devices, endoscopy equipment, infection control, single-use endoscopes
Industry3 codes
1Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
CodeHLAHADABPrimaryYes
2Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
CodeHLAHADAAPrimaryNo
3Reprocessing & Endoscope Infection Prevention (AERs, Drying/Storage, Leak Testing, Brushes)
CodeHLAHANAJPrimaryNo
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices
Cost components5 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vision Sciences develops and manufactures flexible endoscopes designed as an infection-control solution to decrease the risk of cross-contamination during endoscopic procedures. The product line targets healthcare facilities performing diagnostic and therapeutic endoscopy, with an emphasis on disposable or sheathed scope technologies that address hospital-acquired infection risks associated with reusable endoscopes.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Flexible Endoscopes
CategoryMedical Devices / Endoscopy
Description

Flexible endoscopes designed and manufactured by Vision Sciences as a control solution to decrease the risk of cross-contamination, intended for use by healthcare providers performing endoscopic diagnostic and therapeutic procedures.

No data
Peers10 records
TypeDirect peer
Description

Specialist in flexible and rigid endoscopy with strong presence in urology, ENT, and surgical visualization. Directly comparable as a focused endoscopy device maker competing for the same hospital customers and procedural use cases as Vision Sciences.

TypeBroad incumbent
Description

Global leader in flexible endoscopy across GI, urology, and surgical specialties with full procedure-room ecosystems. Comparable to Vision Sciences as the dominant incumbent in the same endoscope category, but with vastly broader portfolio, scale, and installed base.

TypeBroad incumbent
Description

Major flexible endoscopy manufacturer serving GI and pulmonology through its healthcare division. Comparable as a broad incumbent in flexible endoscopes, with deep hospital relationships and integrated imaging platforms that compete against Vision Sciences' products.

TypeBroad incumbent
Description

Diversified medical device company with a portfolio that includes endoscopy and visualization products. Comparable as an incumbent competitor in flexible endoscopy and adjacent surgical visualization categories.

TypeBroad incumbent
Description

Medtech player with women's health endoscopy products including hysteroscopy and related scopes. Comparable as a broad incumbent with overlapping endoscopy portfolio and channel access to specialty procedural customers.

TypeDirect peer
Description

Global leader in endoscope reprocessing and infection prevention, including automated endoscope reprocessors (AERs) and consumables. Comparable to Vision Sciences as a focused player addressing endoscope cross-contamination risk, though through reprocessing rather than scope design.

TypeDirect peer
Description

Provider of endoscope reprocessing equipment, high-level disinfectants, and infection-prevention consumables used by GI and pulmonology departments. Directly comparable as a cross-contamination solution vendor serving the same hospital buyers as Vision Sciences.

TypeBroad incumbent
Description

Large diversified medtech with a meaningful endoscopy and visualization franchise. Comparable as a broad incumbent competing in flexible endoscopy and surgical visualization, with far greater commercial reach than Vision Sciences.

TypeDirect peer
Description

Pioneer and leader in single-use flexible endoscopes explicitly designed to eliminate cross-contamination risk. Highly comparable to Vision Sciences on the cross-contamination value proposition and target customers, and a direct threat given its scale and recent product launches.

TypeBroad incumbent
Description

Diversified medtech with significant GI and pulmonary endoscopy product lines including single-use scopes. Comparable as a broad incumbent and direct competitor in flexible endoscopy channels, particularly as it expands single-use offerings.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vision Sciences

Medical Devicesvisionsciences.com

Vision Sciences is a medical device company that develops flexible endoscopes engineered to reduce cross-contamination risk in clinical settings. Founded in 1987 and headquartered in Orangeburg, it historically served healthcare providers before its NASDAQ delisting.

Vision Sciences firmographics

Firmographics
Name
Vision Sciences
Website
https://visionsciences.com
Company type
Private
Founded year
1987
Operating status
Operating
Headcount range
51–100 employees
Short description
Vision Sciences is a medical device company that develops flexible endoscopes engineered to reduce cross-contamination risk in clinical settings. Founded in 1987 and headquartered in Orangeburg, it historically served healthcare providers before its NASDAQ delisting.
Ownership category
akta.pro rank

Vision Sciences industry classification

Industry
Product category
Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)
akta.pro secondary industries
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA), Reprocessing & Endoscope Infection Prevention (AERs, Drying/Storage, Leak Testing, Brushes) (HLAHANAJ)

Keywords

  • Flexible endoscopes
  • Medical devices
  • Endoscopy equipment
  • Infection control
  • Single-use endoscopes

Where Vision Sciences is headquartered

Location

Headquarters

HQ city
Orangeburg
HQ country
United States
HQ region
North America

Markets served

Vision Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Vision Sciences product offering

Product offering

Core offering

Vision Sciences develops and manufactures flexible endoscopes designed as an infection-control solution to decrease the risk of cross-contamination during endoscopic procedures. The product line targets healthcare facilities performing diagnostic and therapeutic endoscopy, with an emphasis on disposable or sheathed scope technologies that address hospital-acquired infection risks associated with reusable endoscopes.

Differentiator

Problem solved

Functional benefit

Products and services

  • Flexible Endoscopes Flexible endoscopes designed and manufactured by Vision Sciences as a control solution to decrease the risk of cross-contamination, intended for use by healthcare providers performing endoscopic diagnostic and therapeutic procedures.

Companies that use Vision Sciences

Customer profile

Ideal customer profiles1 record

Vision Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Vision Sciences competitors and assessment

Company assessment

Direct peers

  • Karl Storz SE & Co. KG: Specialist in flexible and rigid endoscopy with strong presence in urology, ENT, and surgical visualization. Directly comparable as a focused endoscopy device maker competing for the same hospital customers and procedural use cases as Vision Sciences.
  • Steris plc: Global leader in endoscope reprocessing and infection prevention, including automated endoscope reprocessors (AERs) and consumables. Comparable to Vision Sciences as a focused player addressing endoscope cross-contamination risk, though through reprocessing rather than scope design.
  • Cantel Medical / Medivators: Provider of endoscope reprocessing equipment, high-level disinfectants, and infection-prevention consumables used by GI and pulmonology departments. Directly comparable as a cross-contamination solution vendor serving the same hospital buyers as Vision Sciences.
  • Ambu A/S: Pioneer and leader in single-use flexible endoscopes explicitly designed to eliminate cross-contamination risk. Highly comparable to Vision Sciences on the cross-contamination value proposition and target customers, and a direct threat given its scale and recent product launches.

Broad incumbents

  • Olympus Corporation: Global leader in flexible endoscopy across GI, urology, and surgical specialties with full procedure-room ecosystems. Comparable to Vision Sciences as the dominant incumbent in the same endoscope category, but with vastly broader portfolio, scale, and installed base.
  • Fujifilm Healthcare (formerly Pentax): Major flexible endoscopy manufacturer serving GI and pulmonology through its healthcare division. Comparable as a broad incumbent in flexible endoscopes, with deep hospital relationships and integrated imaging platforms that compete against Vision Sciences' products.
  • CONMED Corporation: Diversified medical device company with a portfolio that includes endoscopy and visualization products. Comparable as an incumbent competitor in flexible endoscopy and adjacent surgical visualization categories.
  • Hologic, Inc. Medtech player with women's health endoscopy products including hysteroscopy and related scopes. Comparable as a broad incumbent with overlapping endoscopy portfolio and channel access to specialty procedural customers.
  • Stryker Corporation: Large diversified medtech with a meaningful endoscopy and visualization franchise. Comparable as a broad incumbent competing in flexible endoscopy and surgical visualization, with far greater commercial reach than Vision Sciences.
  • Boston Scientific Corporation: Diversified medtech with significant GI and pulmonary endoscopy product lines including single-use scopes. Comparable as a broad incumbent and direct competitor in flexible endoscopy channels, particularly as it expands single-use offerings.

Market position

Customer concentration

Vision Sciences social profiles

Digital presence

Vision Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vision Sciences leadership team

Management profile

Number of profiles

Profiles4 records

Vision Sciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vision Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vision Sciences

What does Vision Sciences do?

Vision Sciences develops and manufactures flexible endoscopes designed as an infection-control solution to decrease the risk of cross-contamination during endoscopic procedures. The product line targets healthcare facilities performing diagnostic and therapeutic endoscopy, with an emphasis on disposable or sheathed scope technologies that address hospital-acquired infection risks associated with reusable endoscopes.

When was Vision Sciences founded?

Vision Sciences was founded in 1987. It employs 51 to 100 people.

Where is Vision Sciences based?

Vision Sciences is headquartered in Orangeburg, United States, in the North America region.

Who are Vision Sciences's main competitors?

Direct peers on record are Karl Storz SE & Co. KG, Steris plc, Cantel Medical / Medivators and Ambu A/S. Broad incumbents are Olympus Corporation, Fujifilm Healthcare (formerly Pentax), CONMED Corporation, Hologic, Inc., Stryker Corporation and Boston Scientific Corporation.

Does Vision Sciences have an API?

No public API is recorded for Vision Sciences.

What industry is Vision Sciences in?

Vision Sciences's product category is Medical Devices. Its primary akta.pro industry code is HLAHADAB, Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation), with a secondary code of HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireGERD Awareness Week Puts the Focus on Patient-Centric DiagnosticsGERD Awareness Week runs Nov. 23-29, 2014, with Vision-Sciences promoting its sedation-free Transnasal Esophagoscopy (TNE) as a diagnostic alternative to traditional endoscopy. The TNE system avoids propofol sedation and the gag reflex, allowing patients to drive home or return to work. The company encourages patients to discuss TNE with their physicians.GlobeNewswireVision-Sciences Reports Revenues of $3.4 Million for First Quarter 2013Vision-Sciences reported first-quarter fiscal 2013 net sales of $3.4 million, down 10% year-over-year, with an operating loss of $2.3 million. The company expects revenue growth from new product launches, including shipments to SpineView and Stryker.GlobeNewswireVision-Sciences, Inc. to Present at Lazard Healthcare Conference on November 16, 2011Vision-Sciences, Inc. announced that CEO Cynthia Ansari and CFO Katherine Wolf will present an overview of the company at the Lazard Capital Markets Healthcare Conference in New York on November 16, 2011. The company designs and markets flexible endoscopic products, including the Slide-On EndoSheath System, and owns several registered trademarks.GlobeNewswireVision-Sciences, Inc. Schedules Second Quarter and First Half of Fiscal 2012 Conference Call for November 8, 2011Vision-Sciences, Inc. will issue financial results for the second quarter and first half of fiscal 2012 after market close on November 7, 2011. The company will host a conference call on November 8 at 8:30 am EST to discuss the results and provide an update. A recording and replay will be available through November 15.GlobeNewswireVision-Sciences, Inc. Appoints Cynthia F. Ansari Chief Executive OfficerVision-Sciences, Inc. appointed Cynthia F. Ansari as CEO, effective August 11, replacing interim CEO Warren Bielke. Ansari brings nearly 20 years of medical device experience, including as Stryker Spine's global marketing VP. She will oversee strategic growth of the company's endoscopic products.GlobeNewswireVision-Sciences, Inc. Announces $3.8 Million in Revenue for the First Quarter of Fiscal 2012Vision-Sciences reported Q1 fiscal 2012 net sales of $3.8 million, up 43% year-over-year, driven by urology endoscope and EndoSheath disposables sales. Gross profit rose to $1.1 million (30% margin) and net loss to $2.6 million. The company will hold a conference call on August 11, 2011.GlobeNewswireVision-Sciences, Inc. Schedules Fiscal 2012 Conference Call for August 11, 2011Vision-Sciences, Inc. will issue first-quarter fiscal 2012 financial results after market close on August 10, 2011, and host a conference call on August 11 at 8:30 am EDT. The call will provide an update on the company, with a recording available through August 18.GlobeNewswireVision-Sciences, Inc. Announces Revenue of $3.2 Million for Fourth Quarter and $10.9 Million for Full Year Fiscal 2011Vision-Sciences reported Q4 fiscal 2011 net sales of $3.2 million, up 61% year-over-year, and full-year sales of $10.9 million, up 1%. Pro forma for excluding Medtronic sales, Q4 growth was 88% and full-year 61%. The company expects Stryker's urology product launch to drive fiscal 2012 growth.GlobeNewswireVision-Sciences, Inc. Schedules Fiscal 2011 Conference Call for June 3, 2011Vision-Sciences, Inc. will issue financial results for fiscal 2011 after market close on June 2, 2011, and host a conference call on June 3 at 8:30 am EDT. The call will cover Q4 and full-year results and provide an update, with a recording available through June 10.GlobeNewswireVision-Sciences, Inc. Clarifies Recent Stock Dispositions; Announces Positive ProgressVision-Sciences clarified that recent Form 4 filings by management did not reflect share sales but rather forfeiture of restricted shares tied to unmet performance milestones. The company finished fiscal 2011 strong, and CEO Warren Bielke cited progress in Stryker's domestic product program and airway-related products. He expects positive developments in fiscal 2012.